PHA-022121 low dose ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
65原発性免疫不全症候群2

65. 原発性免疫不全症候群


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05396105
(ClinicalTrials.gov)
December 28, 202228/4/2022Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary AngioedemaA Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)Hereditary Angioedema;Hereditary Angioedema Type I;Hereditary Angioedema Type II;Hereditary Angioedema Types I and II;Hereditary Angioedema Attack;Hereditary Angioedema With C1 Esterase Inhibitor Deficiency;Hereditary Angioedema - Type 1;Hereditary Angioedema - Type 2;C1 Esterase Inhibitor [C1-INH] Deficiency;C1 Esterase Inhibitor Deficiency;C1 Esterase Inhibitor, Deficiency of;C1 Inhibitor DeficiencyDrug: PHA-022121 low dose;Drug: PHA-022121 medium dose;Drug: PHA-022121 high dose;Drug: PHA-022121 selected dosePharvaris Netherlands B.V.NULLRecruiting18 YearsN/AAll72Phase 2/Phase 3United States;Bulgaria;Czechia;France;Germany;Hungary;Spain
2NCT05047185
(ClinicalTrials.gov)
April 19, 20227/9/2021Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type IIA Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)Hereditary Angioedema;Hereditary Angioedema Type I;Hereditary Angioedema Type II;Hereditary Angioedema Types I and II;Hereditary Angioedema Attack;Hereditary Angioedema With C1 Esterase Inhibitor Deficiency;Hereditary Angioedema - Type 1;Hereditary Angioedema - Type 2;C1 Esterase Inhibitor Deficiency;C1 Inhibitor DeficiencyDrug: PHA-022121 low dose;Drug: PHA-022121 high dose;Drug: PlaceboPharvaris Netherlands B.V.NULLRecruiting18 Years75 YearsAll30Phase 2United States;Bulgaria;Canada;Germany;Israel;Italy;Poland;Spain;United Kingdom